National audit of patient reported experience of radical cystectomy for bladder cancer pathways.

The objective of this study was to measure and describe the national patient experience of radical cystectomy (RC) pathways in the UK using the validated Cystectomy-Pathway Assessment Tool (C-PAT).

A cohort of 1081 patients who underwent RC for bladder cancer, between 1 January 2021 and 31 July 2022 at 33 UK cystectomy centres, returned completed C-PAT responses. SPSS was employed for data summary statistics, including median, interquartile range, Mann Whitney U test or Chi-square test with a 95% confidence interval to assess statistical significance between potentially associated variables. Open-text responses in the C-PAT tool were analysed and coded using NVivo software.

In this cohort, the greatest perceived delay in the RC pathway, reported by 19% of patients (n = 208), was at the GP consultation to first hospital referral stage with suspected bladder cancer. Around 10% of patients perceived delays at each of the other stages in their pathway. Cancer nurse specialist (CNS) contact was strongly associated with an improved patient experience (p < 0.001); however, 9.5% of patients reported that they were not assigned a cancer nurse specialist in their pathway. Overall, 96% (n = 1028) reported their experience of RC pathway care to be good or excellent. There were no significant differences in reported patient experience found between cystectomy centres.

This audit demonstrates the feasibility of measuring patient experience of RC pathways at scale. The C-PAT tool demonstrated utility in identifying specific pathway areas for quality improvement. Overall UK patients report a high quality pathway experience. A focus on improving the referral pathway between primary and secondary care is necessary.

BJUI compass. 2024 Aug 19*** epublish ***

Preksha Kuppanda, Louisa Hermans, Alan Uren, Nikki Cotterill, Edward Rowe, Krishna Narahari, Andrew Dickinson, Jeannie Rigby, Jonathan Aning, C‐PAT Study Group (#) and the BAUS Section of Oncology , Jon Featherstone, Emmanuel Okpii

Bristol Urological Institute, Southmead Hospital North Bristol NHS Trust Bristol UK., British Association of Urological Surgeons London UK., Department of Urology Cardiff and Vale University Health Board Cardiff UK., Department of Urology University Hospitals Plymouth Plymouth UK., Action Bladder Cancer UK Tetbury UK.